Emerging evidence suggests microbial dysbiosis may contribute to gynaecological pathologies, including endometriosis and recurrent implantation failure (RIF). The vaginal microbiome is well-characterised, with Lactobacillus-dominance as a hallmark of health, yet …
Endometriosis is a debilitating chronic inflammatory disorder driven by extensive molecular reprogramming. Despite significant bench research into its pathogenesis, translating these molecular discoveries into clinical practices that improve patient outcomes …
Endometriosis is an estrogen-dependent benign inflammatory disorder characterized by the implantation of active endometrial tissue (glands or stroma) outside the uterus, with pelvic adhesions as a core hallmark. Omental endometriosis …
Gesynta Pharma reaches 50% patient enrollment milestone in Phase 2 endometriosis trial Vietnam Investment Review - VIR
Endometriosis is a chronic, estrogen-dependent inflammatory disease sustained by aberrant angiogenesis and progressive fibrosis. We evaluated the therapeutic efficacy of human dental pulp-derived mesenchymal stem cells (DP-MSCs) in a surgically …
After manufacturing changes, the safety and tolerability of the progesterone vaginal ring (PVR) was compared to findings from the similarly designed phase 3 trial. This prospective, open-label, single-arm, multi-center U.S. …
Endometriosis (EMs) is a prevalent gynecological disorder characterized by the ectopic growth of functional endometrial tissue, and its fibrotic pathology represents a primary contributor to chronic pain and infertility in …
Endometriosis is a chronic estrogen-dependent inflammatory disease affecting approximately 10% of women of reproductive age and characterized by ectopic endometrial-like tissue growth. Although traditionally considered a benign gynecological condition, increasing …
Karyopharm Therapeutics stock (US48576U1060): Q1 revenue beats estimates, trial enrollment complete AD HOC NEWS
Karyopharm completes endometrial cancer trial enrollment Investing.com